Tag: TAVR

Teleflex Announces First Patient Enrollment in ACCESS-MANTA™ Registry

Registry Intends to Examine Contemporary On-Label Use of the MANTA™ Vascular Closure Device Including Appropriate Patient Selection and Proper Vascular Access WAYNE, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrollment in a clinical registry […]

Teleflex Receives FDA Clearance for the Wattson® Temporary Pacing Guidewire

Company expands Structural Heart Portfolio with the first commercially available bipolar temporary pacing guidewire designed specifically for use during transcatheter aortic valve replacement (TAVR) and balloon aortic valvuloplasty (BAV) WAYNE, Pa., June 07, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced […]

Valve Medical Announces Successful First-in-Human Implantation of Ultra-low Profile TAVR Valve in Israel

TEL AVIV, Israel, May 31, 2023 /PRNewswire/ — Valve Medical, a wholly owned subsidiary of Medinol Ltd. is pleased to announce today the successful First-in-Human (FIH) implantation of their advanced Transcatheter Aortic Valve Replacement (TAVR) system in Israel, introducing a revolutionary advancement in Structural Heart procedures with the world’s first modular valve. The […]

JenaValve Announces First Trilogy Heart Valve Systems Implanted in Asia

IRVINE, Calif., May 18, 2023 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced the completion of the first two Trilogy Heart Valve System implantations in Asia. The two procedures were performed by Dr. Michael Lee and team at Queen […]

DATA FROM BENCHMARK REGISTRY DEMONSTRATE IMPROVED TAVR EFFICIENCY WITH PRESERVED PATIENT SAFETY

PARIS, May 17, 2023 /PRNewswire/ — Edwards Lifesciences (NYSE: EW) announced today that new data from the Benchmark Registry in Europe demonstrated the safety and effectiveness of this streamlined treatment pathway for patients receiving transcatheter aortic valve replacement (TAVR) with balloon-expandable valves. The data were presented in a late-breaking clinical data session at EuroPCR 2023. […]

Emboline Announces First Patient Treated in IDE Study of Emboliner® Full-Body Embolic Protection Catheter to Minimize Stroke Risk From TAVR

SANTA CRUZ, Calif., May 9, 2023 /PRNewswire/ — Emboline, Inc., a privately held medical technology company focused on reducing stroke during structural heart procedures such as transcatheter aortic valve replacement (TAVR), today announced the first patient has been treated in the Protect the Head to Head investigational device exemption (IDE) clinical trial […]

Capital Health Now Offers Minimally Invasive Aortic Valve Replacement

HOPEWELL, N.J., April 26, 2023 /PRNewswire/ — As part of the growing full-service cardiac program available at Capital Health’s Heart and Vascular Institute, physicians and staff from the Institute’s Structural Heart Program recently performed their first transcatheter aortic valve replacement (TAVR) procedure at Capital Health Regional Medical Center in Trenton, New Jersey. TAVR […]

Morton Plant Hospital’s Patients Reap Benefits from Heart Team’s Vision

CLEARWATER, Fla., April 3, 2023 /PRNewswire/ — Eleven years ago on Feb. 2, 2012, Morton Plant Hospital in Clearwater became the first hospital in the Tampa Bay area to replace a heart valve without open heart surgery. The structural heart team, led by Joshua Rovin, MD, FACS, cardiovascular surgeon and medical director of The Center for Advanced Valve and […]

Medtronic Evolut™ TAVR platform shows excellent valve performance and durability in low-risk aortic stenosis patients

ACC.23/WCC Late-Breaking Clinical Trial: Evolut™ is only TAVR to show excellent outcomes in low-risk patients at 3 years Medtronic today announced three-year data from the Evolut Low Risk Trial, demonstrating the Medtronic EvolutTM transcatheter aortic valve replacement (TAVR) System had numerically better clinical outcomes and significantly better hemodynamic valve performance than […]

EDWARDS HIGHLIGHTS NEW DATA AT ACC RELATED TO LIFETIME MANAGEMENT OF AORTIC STENOSIS

NEW ORLEANS, March 6, 2023 — Edwards Lifesciences (NYSE: EW) today highlighted new important data examining mortality rates and cardiac damage of early-stage aortic stenosis (AS) sufferers, along with data examining 10-year transcatheter aortic valve replacement (TAVR) re-intervention rates using real-world Medicare data.  Together these studies, presented at the American College […]